Is the supplement Medi‑C Plus (vitamin C and lysine) effective for treating atherosclerosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Medi-C Plus is NOT Effective for Treating Atherosclerosis

There is no credible evidence supporting the use of Medi-C Plus (vitamin C and lysine combination) for treating atherosclerosis, and current clinical guidelines universally recommend proven lipid-lowering therapies—specifically statins, ezetimibe, and PCSK9 inhibitors—as the evidence-based standard of care. 1, 2

Why This Supplement Lacks Support

The Evidence Against Vitamin C Supplementation

The research on vitamin C supplementation for atherosclerosis is either negative or contradictory:

  • Large-scale trials show no benefit: The Physicians Health Study II, involving 14,641 participants over 8 years, found vitamin C supplementation had no effect on major cardiovascular events (HR 0.99), total MI (HR 1.04), stroke (HR 0.89), or cardiovascular mortality (HR 1.02) 3

  • Potential harm identified: One prospective cohort study found that high-dose vitamin C supplementation (857-5000 mg/day) was associated with three-fold increased carotid intima-media thickness progression compared to no supplementation (20.3 vs 7.6 μm/year, p<0.001), while vitamin C from food showed protective effects 4

  • Meta-analyses confirm ineffectiveness: A comprehensive meta-analysis of randomized controlled trials found no evidence that antioxidant vitamin supplementation (including vitamin C) slows atherosclerosis progression measured by imaging 5

The Lysine Component Has Minimal Evidence

Only one in vitro study 6 from 2007 showed that a combination of ascorbic acid, lysine, proline, and catechins affected smooth muscle cell behavior in culture. This laboratory finding has never been validated in human clinical trials for cardiovascular outcomes—making it scientifically insufficient to recommend for patient care.

What Actually Works: Evidence-Based Treatment

Current 2024 guidelines provide clear, algorithmic recommendations for atherosclerosis treatment 1:

First-Line Therapy (Class I, Level A)

  • Statins are mandatory for all patients with atherosclerotic disease
  • Target: LDL-C <1.4 mmol/L (55 mg/dL) with >50% reduction from baseline
  • Use high-intensity statins (atorvastatin 40-80 mg or rosuvastatin 20-40 mg)

Second-Line: Add Ezetimibe (Class I, Level B)

  • If LDL-C target not achieved on maximally tolerated statin within 4-6 weeks
  • Combination therapy reduces LDL-C by additional 15-20%

Third-Line: Add PCSK9 Inhibitors (Class I, Level A)

  • If target still not met on statin + ezetimibe
  • Options: alirocumab, evolocumab (every 2-4 weeks), or inclisiran (twice yearly)
  • Can reduce LDL-C by additional 50-60%

Alternative for Statin Intolerance

  • Bempedoic acid alone or with ezetimibe (Class I, Level B)
  • Can be combined with PCSK9 inhibitors if needed

Critical Clinical Pitfalls

Do not delay proven therapy: Patients seeking alternative supplements like Medi-C Plus are losing valuable time. The principle "lower is better for longer" and "the earlier the better" for LDL-C reduction means every month without proper treatment increases cardiovascular risk 2.

Vitamin C from food vs. supplements: While dietary vitamin C from fruits and vegetables is part of a healthy Mediterranean diet (Class I, Level A recommendation) 1, isolated supplementation does not replicate these benefits and may cause harm 4.

The "natural" fallacy: Patients often believe supplements are safer than pharmaceuticals. The evidence shows the opposite—statins have decades of safety data and proven mortality reduction, while high-dose vitamin C supplements have shown potential harm in atherosclerosis progression 4.

The Bottom Line for Clinical Practice

Redirect patients away from Medi-C Plus immediately and initiate guideline-directed medical therapy. The 2024 ESC guidelines are unequivocal: statins are recommended in all patients with peripheral arterial and aortic diseases (Class I, Level A) 1. For patients with established atherosclerotic cardiovascular disease, upfront combination therapy with statin + ezetimibe should be considered, particularly in those with high baseline LDL-C 2.

Emphasize to patients that while a Mediterranean diet rich in vitamin C-containing foods is beneficial 1, isolated vitamin C and lysine supplementation has no role in atherosclerosis treatment and may delay life-saving therapy.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.